Article Text
Commentary
Vulnerable person investigation plan (VIP) to optimise inclusion in clinical trials
Statistics from Altmetric.com
Footnotes
Twitter @IlanaRaburn
Contributors ICR: first author, performed literature review and writing of the manuscript EMB: participated in defining the research area and manuscript direction and editing of manuscript. AJC: last author, supervision of research, participated in defining the research area and manuscript direction and writing and editing the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Should surgical training include involvement in a clinical trial?
- From plans to actions in patient and public involvement: qualitative study of documented plans and the accounts of researchers and patients sampled from a cohort of clinical trials
- Paramedic perceptions of the feasibility and practicalities of prehospital clinical trials: a questionnaire survey
- Clinical trials
- Clinical trial outcomes for SLE: what we have and what we need
- NHS Confederation calls for action to halt loss of clinical trials from UK
- Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
- Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials
- [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
- Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016–2020